3 terminated. 3 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 3 |
| Phase 3 | 1 | Terminated 1 |
Follow Pharming Technologies B.V.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prevention of Acute Kidney Injury in Patients With NSTEMI conestat alfa or placebo - Non-ST Elevation Myocardial Infarction (NSTEMI) | Phase 2 | Terminated | Pharming Technologies B.V. | 29 | 2021-04-21 | 2024-04-03 |
| Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19 Conestat alfa - Coronavirus Infections | Phase 2 | Terminated | University Hospital, Basel, Switzerland | 80 | 2020-08-06 | 2021-11-09 |
| Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI CDZ173 - Activated PI3Kdelta Syndrome (APDS); PASLI Disease | Phase 2 / Phase 3 | Terminated | Pharming Technologies B.V. | 37 | 2016-09-08 | 2026-03-30 |
Activated PI3K-delta Syndrome (1) · Angioedemas, Hereditary (1) · COVID-19 (1) · Coronavirus Infections (1) · Cytokine Release Syndrome (1) · Immunologic Deficiency Syndromes (1) · Lymphadenopathy (1) · Non-ST Elevated Myocardial Infarction (1)
conestat alfa (2) · leniolisib (1)
Switzerland (2) · Belarus (1) · Brazil (1) · Czechia (1) · Germany (1) · Italy (1) · Mexico (1) · Netherlands (1) · Russia (1) · United States (1)
Anurag Relan, MD (1) · Michael Osthoff, PD Dr. med. (1)
PMID 33397449, PMID 37797893, PMID 37965347, PMID 38593221
2016 (1)